Education
About Us
Working with TipRanks
Follow Us
Pacific Biosciences (PACB)
NASDAQ:PACB
Earnings Data
Report Date
Feb 12, 2026TBA (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.15Last Year’s EPS
0.01Same Quarter Last Year
Moderate Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive and negative aspects. While there were significant achievements in consumable revenue, gross margin improvements, and clinical advancements, these were tempered by an overall decline in total revenue and challenges in the funding environment impacting instrument sales.Company Guidance
Record Consumable Revenue
Consumable revenue reached an all-time high of $21.3 million, growing 15% year-over-year and 12% sequentially, driven by strong adoption of long-read sequencing technology.
Improved Gross Margins
Non-GAAP gross margins were 42%, the highest level since 2022, due to increased consumable revenue and improved product mix.
Strong EMEA Growth
EMEA revenue increased by 18% year-over-year, driven by a 50% increase in consumable revenue.
Cash Burn Reduction
Cash burn reduced to $16 million in Q3, with an expected total cash burn of approximately $115 million for 2025, an improvement of over $70 million compared to 2024.
Clinical Advancements and Partnerships
Secured China regulatory approval for Sequel II CNDx system for clinical-grade long-read sequencing, and announced partnerships to expand clinical assay use.
New Chemistry SPRQ-Nx Launched
Unveiled the SPRQ-Nx chemistry, expected to lower sequencing costs to less than $300 per genome and improve gross margins through multi-use SMRT Cells.
PACB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
PACB Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 05, 2025 | $1.92 | $1.78 | -7.29% |
Aug 07, 2025 | $1.26 | $1.35 | +7.14% |
May 08, 2025 | $1.20 | $1.12 | -6.67% |
Feb 13, 2025 | $1.48 | $1.85 | +25.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Pacific Biosciences (PACB) report earnings?
Pacific Biosciences (PACB) is schdueled to report earning on Feb 12, 2026, TBA (Confirmed).
What is Pacific Biosciences (PACB) earnings time?
Pacific Biosciences (PACB) earnings time is at Feb 12, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PACB EPS forecast?
PACB EPS forecast for the fiscal quarter 2025 (Q4) is -0.15.